APO Research
Talk to an analyst

APO RESEARCH · REPORT

Ulcerative Colitis Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Ulcerative Colitis Drugs Market Outlook and Growth Opportunities 2026

22 December 2025192 pages

Choose your research edition.

Industry ResearchUlcerative Colitis Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Ulcerative Colitis Drugs Industry Growth and Trends Forecast to 2032113 pages · $3,450 USDMarket StructureGlobal Ulcerative Colitis Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Ulcerative Colitis Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Ulcerative Colitis Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Ulcerative Colitis Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Ulcerative Colitis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Ulcerative Colitis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Ulcerative Colitis Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Ulcerative Colitis Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Ulcerative Colitis Drugs market include Takeda Pharmaceuticals Company, Sanofi, Johnson & Johnson, Novartis, Roche, Eli Lilly and Company, Pfizer, Ferring Pharmaceuticals and GSK, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Ulcerative Colitis Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Ulcerative Colitis Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Ulcerative Colitis Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Ulcerative Colitis Drugs market.

Ulcerative Colitis Drugs Segment by Company

Takeda Pharmaceuticals Company

Sanofi

Johnson & Johnson

Novartis

Roche

Eli Lilly and Company

Pfizer

Ferring Pharmaceuticals

GSK

Bayer

Amgen

AbbVie

AstraZeneca

MSD

InDeX Pharmaceuticals

Ulcerative Colitis Drugs Segment by Type

Oral

Injection

Ulcerative Colitis Drugs Segment by Application

Hospital

Drugs Stores

Ulcerative Colitis Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Ulcerative Colitis Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Ulcerative Colitis Drugs key companies, revenue, market share, and recent developments.

3. To split the Ulcerative Colitis Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Ulcerative Colitis Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Ulcerative Colitis Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Ulcerative Colitis Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ulcerative Colitis Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Ulcerative Colitis Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ulcerative Colitis Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Ulcerative Colitis Drugs industry.

Chapter 3: Detailed analysis of Ulcerative Colitis Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Ulcerative Colitis Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Ulcerative Colitis Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Ulcerative Colitis Drugs Industry Trends Table 2. Ulcerative Colitis Drugs Industry Drivers Table 3. Ulcerative Colitis Drugs Industry Opportunities and Challenges Table 4. Ulcerative Colitis Drugs Industry Restraints Table 5. Global Ulcerative Colitis Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Ulcerative Colitis Drugs Revenue Share by Company (2021-2026) Table 7. Global Ulcerative Colitis Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Ulcerative Colitis Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Ulcerative Colitis Drugs Company, Product Type & Application Table 10. Global Ulcerative Colitis Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Ulcerative Colitis Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Table 15. Significant Companies of Injection Table 16. Global Ulcerative Colitis Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Ulcerative Colitis Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Ulcerative Colitis Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Ulcerative Colitis Drugs Sales Value Share by Type (2021-2026) Table 20. Global Ulcerative Colitis Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Drugs Stores Table 23. Global Ulcerative Colitis Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Ulcerative Colitis Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Ulcerative Colitis Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Ulcerative Colitis Drugs Sales Value Share by Application (2021-2026) Table 27. Global Ulcerative Colitis Drugs Sales Value Share by Application (2027-2032) Table 28. Global Ulcerative Colitis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Ulcerative Colitis Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Ulcerative Colitis Drugs Sales Value Share by Region (2021-2026) Table 31. Global Ulcerative Colitis Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Ulcerative Colitis Drugs Sales Value Share by Region (2027-2032) Table 33. Global Ulcerative Colitis Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Ulcerative Colitis Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Ulcerative Colitis Drugs Sales Value Market Share by Country (2021-2026) Table 36. Global Ulcerative Colitis Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Ulcerative Colitis Drugs Sales Value Market Share by Country (2027-2032) Table 38. Takeda Pharmaceuticals Company Company Information Table 39. Takeda Pharmaceuticals Company Business Overview Table 40. Takeda Pharmaceuticals Company Ulcerative Colitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Takeda Pharmaceuticals Company Ulcerative Colitis Drugs Product Portfolio Table 42. Takeda Pharmaceuticals Company Recent Development Table 43. Sanofi Company Information Table 44. Sanofi Business Overview Table 45. Sanofi Ulcerative Colitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Sanofi Ulcerative Colitis Drugs Product Portfolio Table 47. Sanofi Recent Development Table 48. Johnson & Johnson Company Information Table 49. Johnson & Johnson Business Overview Table 50. Johnson & Johnson Ulcerative Colitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Johnson & Johnson Ulcerative Colitis Drugs Product Portfolio Table 52. Johnson & Johnson Recent Development Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis Ulcerative Colitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Novartis Ulcerative Colitis Drugs Product Portfolio Table 57. Novartis Recent Development Table 58. Roche Company Information Table 59. Roche Business Overview Table 60. Roche Ulcerative Colitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Roche Ulcerative Colitis Drugs Product Portfolio Table 62. Roche Recent Development Table 63. Eli Lilly and Company Company Information Table 64. Eli Lilly and Company Business Overview Table 65. Eli Lilly and Company Ulcerative Colitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Eli Lilly and Company Ulcerative Colitis Drugs Product Portfolio Table 67. Eli Lilly and Company Recent Development Table 68. Pfizer Company Information Table 69. Pfizer Business Overview Table 70. Pfizer Ulcerative Colitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Pfizer Ulcerative Colitis Drugs Product Portfolio Table 72. Pfizer Recent Development Table 73. Ferring Pharmaceuticals Company Information Table 74. Ferring Pharmaceuticals Business Overview Table 75. Ferring Pharmaceuticals Ulcerative Colitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Ferring Pharmaceuticals Ulcerative Colitis Drugs Product Portfolio Table 77. Ferring Pharmaceuticals Recent Development Table 78. GSK Company Information Table 79. GSK Business Overview Table 80. GSK Ulcerative Colitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. GSK Ulcerative Colitis Drugs Product Portfolio Table 82. GSK Recent Development Table 83. Bayer Company Information Table 84. Bayer Business Overview Table 85. Bayer Ulcerative Colitis Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Bayer Ulcerative Colitis Drugs Product Portfolio Table 87. Bayer Recent Development Table 88. Amgen Company Information Table 89. Amgen Business Overview Table 90. Amgen Ulcerative Colitis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 91. Amgen Ulcerative Colitis Drugs Product Portfolio Table 92. Amgen Recent Development Table 93. AbbVie Company Information Table 94. AbbVie Business Overview Table 95. AbbVie Ulcerative Colitis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 96. AbbVie Ulcerative Colitis Drugs Product Portfolio Table 97. AbbVie Recent Development Table 98. AstraZeneca Company Information Table 99. AstraZeneca Business Overview Table 100. AstraZeneca Ulcerative Colitis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 101. AstraZeneca Ulcerative Colitis Drugs Product Portfolio Table 102. AstraZeneca Recent Development Table 103. MSD Company Information Table 104. MSD Business Overview Table 105. MSD Ulcerative Colitis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 106. MSD Ulcerative Colitis Drugs Product Portfolio Table 107. MSD Recent Development Table 108. InDeX Pharmaceuticals Company Information Table 109. InDeX Pharmaceuticals Business Overview Table 110. InDeX Pharmaceuticals Ulcerative Colitis Drugs Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 111. InDeX Pharmaceuticals Ulcerative Colitis Drugs Product Portfolio Table 112. InDeX Pharmaceuticals Recent Development Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. Ulcerative Colitis Drugs Product Image Figure 2. Global Ulcerative Colitis Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Ulcerative Colitis Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Ulcerative Colitis Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Image Figure 8. Injection Image Figure 9. Global Ulcerative Colitis Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Ulcerative Colitis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Ulcerative Colitis Drugs Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Drugs Stores Image Figure 14. Global Ulcerative Colitis Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Ulcerative Colitis Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Ulcerative Colitis Drugs Sales Value Share by Application (2021-2032) Figure 17. Global Ulcerative Colitis Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Ulcerative Colitis Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Ulcerative Colitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 20. North America Ulcerative Colitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Ulcerative Colitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Ulcerative Colitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Ulcerative Colitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Ulcerative Colitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Ulcerative Colitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 26. South America Ulcerative Colitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Ulcerative Colitis Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Ulcerative Colitis Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Drugs Stores
Companies covered
  • Takeda Pharmaceuticals Company
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Roche
  • Eli Lilly and Company
  • Pfizer
  • Ferring Pharmaceuticals
  • GSK
  • Bayer
  • Amgen
  • AbbVie
  • AstraZeneca
  • MSD
  • InDeX Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Ulcerative Colitis Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Ulcerative Colitis Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Ulcerative Colitis Drugs Market Dynamics
  1. 2.1 Ulcerative Colitis Drugs Industry Trends
  2. 2.2 Ulcerative Colitis Drugs Industry Drivers
  3. 2.3 Ulcerative Colitis Drugs Industry Opportunities and Challenges
  4. 2.4 Ulcerative Colitis Drugs Industry Restraints
3 Ulcerative Colitis Drugs Market by Company
  1. 3.1 Global Ulcerative Colitis Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Ulcerative Colitis Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Ulcerative Colitis Drugs Company Ranking (2024-2026)
  4. 3.4 Global Ulcerative Colitis Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Ulcerative Colitis Drugs Company Product Type and Application
  6. 3.6 Global Ulcerative Colitis Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Ulcerative Colitis Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Ulcerative Colitis Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Ulcerative Colitis Drugs Market by Type
  1. 4.1 Ulcerative Colitis Drugs Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global Ulcerative Colitis Drugs Sales Value by Type
  5. 4.2.1 Global Ulcerative Colitis Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Ulcerative Colitis Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Ulcerative Colitis Drugs Sales Value Share by Type (2021-2032)
5 Ulcerative Colitis Drugs Market by Application
  1. 5.1 Ulcerative Colitis Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drugs Stores
  4. 5.2 Global Ulcerative Colitis Drugs Sales Value by Application
  5. 5.2.1 Global Ulcerative Colitis Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Ulcerative Colitis Drugs Sales Value by Application (2021-2032)
  7. 5.2.3 Global Ulcerative Colitis Drugs Sales Value Share by Application (2021-2032)
6 Ulcerative Colitis Drugs Regional Value Analysis
  1. 6.1 Global Ulcerative Colitis Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Ulcerative Colitis Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Ulcerative Colitis Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Ulcerative Colitis Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Ulcerative Colitis Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Ulcerative Colitis Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Ulcerative Colitis Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Ulcerative Colitis Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Ulcerative Colitis Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Ulcerative Colitis Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Ulcerative Colitis Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Ulcerative Colitis Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Ulcerative Colitis Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Ulcerative Colitis Drugs Sales Value Share by Country, 2025 VS 2032
7 Ulcerative Colitis Drugs Country-level Value Analysis
  1. 7.1 Global Ulcerative Colitis Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Ulcerative Colitis Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Ulcerative Colitis Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Ulcerative Colitis Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Ulcerative Colitis Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Ulcerative Colitis Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Ulcerative Colitis Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals Company
  2. 8.1.1 Takeda Pharmaceuticals Company Company Information
  3. 8.1.2 Takeda Pharmaceuticals Company Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Company Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Company Ulcerative Colitis Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Company Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi Ulcerative Colitis Drugs Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Ulcerative Colitis Drugs Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis Ulcerative Colitis Drugs Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Ulcerative Colitis Drugs Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Eli Lilly and Company
  32. 8.6.1 Eli Lilly and Company Company Information
  33. 8.6.2 Eli Lilly and Company Business Overview
  34. 8.6.3 Eli Lilly and Company Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly and Company Ulcerative Colitis Drugs Product Portfolio
  36. 8.6.5 Eli Lilly and Company Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Ulcerative Colitis Drugs Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Ferring Pharmaceuticals
  44. 8.8.1 Ferring Pharmaceuticals Company Information
  45. 8.8.2 Ferring Pharmaceuticals Business Overview
  46. 8.8.3 Ferring Pharmaceuticals Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ferring Pharmaceuticals Ulcerative Colitis Drugs Product Portfolio
  48. 8.8.5 Ferring Pharmaceuticals Recent Developments
  49. 8.9 GSK
  50. 8.9.1 GSK Company Information
  51. 8.9.2 GSK Business Overview
  52. 8.9.3 GSK Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GSK Ulcerative Colitis Drugs Product Portfolio
  54. 8.9.5 GSK Recent Developments
  55. 8.10 Bayer
  56. 8.10.1 Bayer Company Information
  57. 8.10.2 Bayer Business Overview
  58. 8.10.3 Bayer Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bayer Ulcerative Colitis Drugs Product Portfolio
  60. 8.10.5 Bayer Recent Developments
  61. 8.11 Amgen
  62. 8.11.1 Amgen Company Information
  63. 8.11.2 Amgen Business Overview
  64. 8.11.3 Amgen Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Amgen Ulcerative Colitis Drugs Product Portfolio
  66. 8.11.5 Amgen Recent Developments
  67. 8.12 AbbVie
  68. 8.12.1 AbbVie Company Information
  69. 8.12.2 AbbVie Business Overview
  70. 8.12.3 AbbVie Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AbbVie Ulcerative Colitis Drugs Product Portfolio
  72. 8.12.5 AbbVie Recent Developments
  73. 8.13 AstraZeneca
  74. 8.13.1 AstraZeneca Company Information
  75. 8.13.2 AstraZeneca Business Overview
  76. 8.13.3 AstraZeneca Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AstraZeneca Ulcerative Colitis Drugs Product Portfolio
  78. 8.13.5 AstraZeneca Recent Developments
  79. 8.14 MSD
  80. 8.14.1 MSD Company Information
  81. 8.14.2 MSD Business Overview
  82. 8.14.3 MSD Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 MSD Ulcerative Colitis Drugs Product Portfolio
  84. 8.14.5 MSD Recent Developments
  85. 8.15 InDeX Pharmaceuticals
  86. 8.15.1 InDeX Pharmaceuticals Company Information
  87. 8.15.2 InDeX Pharmaceuticals Business Overview
  88. 8.15.3 InDeX Pharmaceuticals Ulcerative Colitis Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 InDeX Pharmaceuticals Ulcerative Colitis Drugs Product Portfolio
  90. 8.15.5 InDeX Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst